medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303198; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

# Blood lead levels and bladder cancer among US participants: NHANES 1999–2018

### Mei Huang<sup>\*</sup>, Hongxiao Li<sup>\*</sup>, Jiahui Chen, Liuqiang Li, Yifei Zhan, Yuxuan Du, Jun Bian<sup>#</sup>, Meiling Chen<sup>#</sup>, Dehui Lai<sup>#</sup>

\*These authors contributed equally to this work.

# corresponding author

1.Key Laboratory of Biological Targeting Diagnosis, Department of Urology, Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

#### 11 **Correspondent:**

12 Dehui Lai

- dehuilai@hotmail.com 13
- Jun Bian 14

1

2 3

4

5 6 7

8

9 10

22

bianjun39@163.com 15

- Meiling Chen 16
- 17 416406696@gg.com

621 Gangwan Road, Huangpu District, Guangzhou City, Guangdong Province 18

### 19 **Conflict of Interest** 20

The authors declare they have no actual or potential competing financial interests. 21

23 Background: Lead is a toxic metal for human health, but its carcinogenicity is 24 controversial, and the effect on bladder cancer is still unknown. The object of this study was to demonstrate the link between blood lead and bladder cancer. 25

**Objectives:** We investigated associations of lead exposures with bladder cancer. 26

Methods: We used the database from the National Health and Nutrition Examination 27

28 Survey (NHANES, 1999–2018) to perform a cross-sectional study. We performed

Weighted multivariate logistic regression to examine the association between blood 29

30 lead level with bladder cancer, and then a subgroup analysis was performed. The

nonlinear association between BLL and bladder cancer was described using fitted 31 smoothing curves. 32

**Results:** A total of 40,486 participants were included in this study, the mean (SD) 33 BMI was  $28.71 \pm 6.68$  kg/m<sup>2</sup>. A fully adjusted model showed that BLL was parallel 34

associated with bladder cancer (Odds ratio [OR] = 2.946, 95% Confidence interval 35 36 [CI] = 1.025 to 8.465, P = 0.047) in people with BMI < 28kg/m<sup>2</sup>. However, no

difference was found in BMI 228kg/m2 subgroup and in General population. In 37

38 NOTE the roup analysis of participants with BMI see Revenand should be used was interested to a second the participants with a second secon

with bladder cancer in the male, non-hypertensive, < 70 year old subgroup (p < 0.05), 39 but was not significantly different from the other subgroups. Additionally, we 40 discovered a non-linear association between BLL and bladder cancer using a linear 41 42 regression model.

43 **Discussion:** In this cross-sectional study, we identified higher BLL level was

44 independently associated with Bladder cancer in People with BMI < 28kg/m<sup>2</sup>. The

results compensated for earlier investigations, but more large-scale prospective 45

- cohorts were required for validation. 46
- 47

Keywords: Blood lead level (BLL), Bladder cancer, NHANES (National Health and 48 Nutrition Examination Survey) 49

50

### 51 Introduction

Lead is a heavy metal that can cause environmental pollution and is poisonous. It 52 is widely found in life, such as mining, welding, batteries, making stained glass, 53 ceramics, especially in low - and middle-income countries(Mitra et al. 2017; 54 55 Obeng-Gyasi 2019; Walter 2023). Lead is difficult to decompose and can be divided into organic and inorganic forms. It mainly enters the human body through digestion, 56 respiration and skin(Fu and Xi 2020). The absorption rate can vary from 10-50% 57 according to the state of the exposed person and the physicochemical factors of 58 lead(Huang 2022). 5mg/dl for adults and 3.5ug/dl for children was defined as 59 reference value, but the threshold of harmful concentration is not clear(Ruckart et al. 60 2021). Lead affects cell metabolism by affecting antioxidant reaction, key enzymes 61 and various hormone activities. Oxidative stress reactions caused by heavy metals can 62 also cause cancer by interfering with DNA repair (Dhir et al. 2011; Flora et al. 2008; 63 Genestra 2007). Recently, with the progress of social industrialization, human health 64 is increasingly affected by heavy metals(Rusyniak et al. 2010). 65

Bladder cancer is the second most common malignancy of the urinary system 66 and ranks 10th in absolute incidence worldwide, with 549,000 new cases and 67 68 approximately 200,000 deaths annually. In the United States, bladder cancer is the sixth highest incidence of cancer. Urothelial carcinoma is the main type of bladder 69 cancer, accounting for more than 90%. Of all cancers, bladder cancer has the highest 70 lifetime treatment costs, with total annual treatment costs of around €3.6 billion in the 71 United States and nearly €5 billion in Europe, adding to the burden on the global 72 73 economy. Smoking is the strongest risk factor, but occupational and environmental 74 toxins also significantly increase the disease burden of bladder cancer(Compérat et al. 2022; Richters et al. 2020; Saginala et al. 2020). 75

There are many reports about the harm of lead to human body, such as type 2 76 diabetes(Zhu et al. 2022), urinary incontinence(Ni et al. 2022), hypertension(Huang 77 2022; Tang et al. 2022), cirrhosis of liver(Reja et al. 2020), lung cancer(Rhee et al. 78 2021), kidney function, Neuropsychiatric problems and endocrine diseases(Qayyum 79 80 et al. 2012; Walter 2023), but there are few reports about the correlation between lead and bladder cancer, whether lead is a risk factor for bladder cancer is still 81 controversial. This study aims to reveal the relationship between the lead and bladder 82

83 cancer.

84

### Methods 85

#### Study population 86

NHANES is a nationally representative survey which was designed to assess the 87 health and nutrition status of adults and children in the United States. Socioeconomic 88 status, diet, medical and physiological examinations and laboratory tests, were 89 conducted on the participants. The database for this article is available from this 90 website (https://www.cdc.gov/nchs/NHANES/index.htm). We analyzed the data from 91 the NHANES survey cycles (1999-2018). In short, To explore a nationally 92 representative sample, NHANES adopts a complicated, multistage probability 93 94 sampling approach among the civilian, noninstitutionalized US population. All 95 participants completed household questionnaires administered by trained research personnel, which included demographic and health history questions. Standardized 96 medical examinations, blood sample collection, and other in-person testing at mobile 97 examination facilities are also part of the research procedure. All NHANES 98 participants provided informed consent. During 1999-2018 NHANES cycles, 101,316 99 100 participants were investigated. There were 25,555 participants without blood lead data. Participants without cancer data or had other cancers were excluded in this 101 102 study(n=35275). The final study population of this study was 40,486. The process of recruiting is shown in Figure 1. 103

104

### Study Variable 105

### Blood Lead 106

The blood lead levels were examined at the Environmental Health Sciences 107 Laboratory of the Center for Disease Control and Prevention (CDC) National Center 108 109 for Environmental Health (NCEH). To assess the blood lead level, venous blood was obtained. Before measuring, blood samples were simply diluted and kept at -20°C. 110 The blood lead level was measured in the central laboSpectrometer (ELAN DRC II, 111 PerkinElmer, Norwalk) in accordance with the usual meratory using an Inductively 112 Coupled Plasma Dynamic Reaction Cell Mass thodology. The lower limits of 113 detection (LOD) for blood lead were different in each NHANES cycle, which are 114 summarized in Table 1. The detection rates of blood lead for participants is 99.7%. All 115 blood lead levels less than the lower limit of detection were replaced with the lower 116 limit of detection multiplied by  $\sqrt{2}$ . The specific laboratory method, detection limit, 117 and other data can be obtained on the official website. 118

119

### 120 Bladder cancer

The answer to the question "Ever been told you had cancer or malignancy?" on the 121 MCQ questionnaire was used for learning whether the participants had cancer or 122 malignancy. The answer to the question "What kind of cancer was it?" gave the 123 location of cancer. 124

125

Other clinical Variable 126

Data on age, sex, race, education, marital, ratio of family income to poverty (PIR), 127 BMI, alcohol, high blood pressure, diabetes, creatinine level, smoke were also 128 collected. Age, sex, race, education, marriage, and PIR can be obtained from 129 demographic information (DEMO). The information of hypertension, diabetes, 130 131 smoking and drinking can be obtained from questionnaires BPO, DIO, SMO and 132 QLQ respectively. BMI was obtained in the physical examination and blood creatinine in the column of laboratory examination. More details of these covariate 133 data can be found in www.cdc.gov/nchs/NHANES/. Mean values are used when the 134 covariates of continuous variables are missing(PIR 2.98, BMI 28.71, blood creatine 135 77.10 umol/L). The classification of all variables is shown in Table 2. 136

137

#### 138 Statistical Analyses

139 All the analyses were performed with R (version 3.4.3, http://www.R-project.org) and Empower Stats software (http://www.empowerstats.com), Stata/MP16.0. Continuous 140 variables were reported as mean  $\pm$  standard deviation (SD), while the categorical 141 variables were percentages. Baseline characteristics were analyzed by a linear 142 143 regression model for continuous variables and a chi-square test for categorical 144 variables, respectively. We divided the blood lead concentration into four categories. Weighted multivariate logistic regression models were performed to explore the 145 146 independent association of blood lead concentration with bladder cancer after adjusting for potential confounding factors. Three models were built: Model 1, an 147 unadjusted model; Model 2, minimally adjusted model (adjusted for age, sex, race, 148 education, marital and PIR), and Model 3, a fully adjusted model (adjusted for age, 149 sex, race, education, marital and PIR, BMI, alcohol use, high blood pressure, diabetes 150 and creatinine level, smoke). BMI-stratified subgroup analysis was performed and 151 Further stratified logistic regression analysis was conducted to clarify the association 152 between Blood lead level (BLL) and bladder cancer. Multivariate tests were 153 constructed by controlling for variables and fitting a smooth curve. Subgroup analyses 154 were performed and they were stratified by sex, age, high blood pressure and PIR. 155 The value of p < 0.05 was considered statistically significant. 156

157

#### **Results** 158

#### 159 **Baseline** Characteristic

160 The clinical characteristics of the participants according to blood lead level as a column stratified variable are shown in Table 2. A total of 40,486 participants aged 161 162 20-85 years who had measured data for blood lead and bladder cancer were included in this study. Of all the participants, there were 48.77% were men, and the mean age 163 was  $45.55 \pm 16.37$ . Participants had an average BMI of 28.71, the gender ratio was 164 roughly equal, and more than half of the participants were non-Hispanic white, had a 165 high school education or more, and were married or living with a partner. Most people 166 did not have high blood pressure and diabetes, but most people had a history of 167 168 alcohol consumption, mostly moderate alcohol consumption. More than half of the participants were non-smokers. There were 0.17% of the participants with bladder 169 170 cancer.

Participants who fell into the Quartile 4 group tended to be older, male, lower 171 PIR and BMI, higher creatinine level, Non-Hispanic white, married or living with a 172 partner, heavy alcohol consumption, smoker, without hypertension or diabetes. 173 Besides, participants who are older, male, lower PIR and BMI, higher creatinine level, 174 high school diploma or below, heavy alcohol consumption, former or current smoker, 175 176 with hypertension and bladder cancer patients are more likely to have higher blood lead level. 177

We can draw the following conclusions from the Table 2: Blood lead levels were 178 associated with age, sex, education, PIR, BMI, creatinine levels, smoking and alcohol 179 consumption, bladder cancer and high blood pressure (p<0.001). The correlation 180 between blood lead and blood pressure is consistent with the results reported by 181 182 predecessors

183 184

### The Association of Blood Lead Concentration With bladder cancer

Table 3 showed the results of the multivariable regression analysis between BLL 185 and bladder cancer. In unadjusted model 1, we observed statistically significant 186 associations between elevated BLLs and bladder cancer (OR 6.350, 95% CI 4.048, 187 188 9.961, P < 0.001). The risk of bladder cancer in the highest quartile array was 16.387 times higher than in the lowest group. After adjusting covariates, however, these 189 190 associations weakened substantially and were no longer statistically significant in model 2 (OR 3.316, 95% CI 1.161, 9.437, P= 0.027) and model3 (OR 2.280,95% CI 191 0.575,9.038, P=0.243). When adjusting BMI<28kg/m<sup>2</sup> (Table 4), the univariate and 192 multivariate analyses demonstrated high BLL was associated with a higher risk of 193 194 bladder cancer in the crude model (OR 7.379, 95% CI 3.959,13.751, P < 0.001), 195 model 2 (OR 3.649, 95% CI 1.380, 9.649, P=0.010), and modle 3(OR 2.946, 95% CI 1.025,8.465, P=0.047). We can draw a conclusion from Table 4 that after adjusting for 196 all confounding factors, BLLs was still positively associated with bladder cancer in 197 the population with BMI  $\leq 28$ kg/m<sup>2</sup> (P=0.047). The correlation was not found when 198 weighted multivariate logistic regression analysis was conducted in BMI ≥28kg/m<sup>2</sup> 199 group, suggesting that no potential modifiers in the relationship between BLLs and 200 bladder cancer in obese population (Table 5). 201

The weighted characteristics of the population with  $BMI < 28 kg/m^2$  are shown in 202 Table 6. 203

Further subgroup analysis of participants with  $BMI < 28 kg/m^2$  was conducted, 204 the result is shown in Table 7. Blood lead was associated with bladder cancer in the 205 male (P=0.01), less than 70 year old (P<0.01), non-hypertensive (P=0.01) subgroup, 206 207 but was not significantly different from the other subgroups.

208 The nonlinear association between BLLs and bladder cancer was then described 209 using smoothed curve fitting (Figures 2 and 3). Figure 2 shows a nonlinear 210 relationship between BLLs and bladder cancer in the general population. Adjusted 211 variables: age, sex, race, education, marital, PIR, BMI, alcohol, high blood pressure, 212 diabetes, creatinine level, smoke. In people with a BMI $\leq 28$ kg/m<sup>2</sup>, a clear rising curve 213 was detected, as shown in Figure 3. Adjusted variables: age, sex, race, education, 214 marital, PIR, alcohol, high blood pressure, diabetes, creatinine level, smoke.

215

#### Discussion 216

In this cross-sectional study from NHANES 1999-2018, we identified higher 217 BLLs was independently associated with Bladder cancer in people with BMI <218 28kg/m<sup>2</sup>, demonstrated that blood lead is the risk factor for bladder cancer in this 219 group, although there was no significant difference in general population. BMI> 220 28kg/m<sup>2</sup> is defined as obesity, however we did not find a clear association between 221 BLL and bladder cancer in obese people. 222

Lead is a heavy metal which can be found in many places. It can enter and 223 accumulate in the human body through different ways. Accumulation in various 224 organs will cause adverse reactions and may damage hematopoietic function, nervous 225 226 system, cardiovascular system, reproductive system, urinary system, digestive system, 227 etc(Ni et al. 2022; Qayyum et al. 2012; Rehman et al. 2018; Reja et al. 2020; Rhee et al. 2021; Tang et al. 2022; Zhu et al. 2022). It can lead not only to neuropsychiatric 228 diseases but also to the progression of cancer(Ebrahimi et al. 2020). According to the 229 International Agency for Research on Cancer (IACR), lead and its compounds are 230 classified as "probable" human carcinogens (Group 2A)([Anonymous] 2006), and 231 there are many articles revealing that lead may cause cancer. By measuring the 232 chemical composition of breast cancer tissues and evaluating the DNA methylation 233 234 level, a study involving 40 breast cancer tissues and 20 normal breast tissue found that the increase of heavy metals in tumor tissues was accompanied by the increase of the 235 expression of HER2/neu, p53, Ki-67 and MGMT, and the decrease of the expression 236 of ER and PR. Pathological DNA methylation increased with the increase of heavy 237 metal content in tumor tissue, and the results showed that the average lead 238 239 concentration in breast cancer tissue was almost three times that of healthy breast tissue, which means that heavy metals stimulate breast cancer progression and reduce 240 241 its sensitivity to treatment(Romaniuk et al. 2017). A review suggests that lead concentrations may be associated with the development and progression of 242 gynecological tumors such as cervical cancer, endometrial cancer, and ovaries(Furtak 243 et al. 2022). In addition, Basu S et al. measured the levels of heavy metals in serum, 244 bile, gallstones and gallbladder of 30 patients with gallbladder cancer and 30 patients 245 with cholelithiasis by atomic absorption spectrophotometry and compared the 246 measured results. It was found that the levels of selenium and zinc in serum, bile and 247 248 gallbladder of patients with gallbladder cancer were significantly reduced, and the concentration of copper was significantly increased. Patients with gallbladder cancer 249 250 have elevated levels of lead, cadmium, chromium and nickel in serum and bile(Basu et al. 2013). Taking 56 hair samples (aged 37 to 74 years) and 43 nail samples (aged 251 38 to 72 years) from untreated lung cancer patients, 54 scalp hair samples (aged 20 to 252 63 years) and 45 nail samples (aged 34 to 63 years) from healthy subjects. Then the 253 heavy metal content of the samples was determined by flame atomic absorption 254 spectrophotometer (Shimadzu AA-670, Japan), and the conclusion was finally drawn 255 by Qayyum MA et al.: The majority of metals (Cd, Pb, Co, Ni, and Cu) in the scalp 256 hair and nails of lung cancer patients were significantly higher than in the control 257 group, and there was considerable variation in metal levels for different stages and 258

types of lung cancer(Qayyum and Shah 2014a). In addition to pancreatic cancer, 259 Oavvum MA et al. also clarified through the same method that the content of Pb in the 260 blood and hair of prostate cancer patients was significantly higher than that of the 261 control group(Qayyum and Shah 2014b). A systematic review and meta-analysis 262 263 suggested that lead exposure was not associated with the risk of both benign and malignant brain tumors (pooled OR = 1.11, 95% CI: 0.95,1.29), but was associated 264 with malignant brain tumors (pooled OR = 1.13, 95% CI: 1.04,1.24)(Ahn et al. 2020). 265 Besides, in a study involving 188 exocrine pancreatic carcinoma and 399 control 266 cases, Amaral AF et al. used inductively coupled plasma-mass spectrometry to 267 determine trace element spectrometry for toenails. The results showed that the content 268 of cadmium and lead in toenail was significantly higher than that in control group 269 270 (P<0.001), and lead was associated with an increased risk of pancreatic excrine carcinoma (OR=6.26, 95%CI 2.71, 14.47; Ptrend= $3 \times 10^{-5}$ )(Amaral et al. 2012). 271

But there are also articles suggesting that lead is not clearly associated with some 272 cancers. A case-control study investigated the occupational elements associated with 273 lung cancer in 1593 male lung cancer patients and 1426 general population.Lifetime 274 275 occupational exposure was assessed using expert-based blinded assessment, and 276 adjustments were made for several potential confounding factors. Ultimately, it was concluded that exposure to lead compounds does not increase the risk of lung 277 278 cancer(Wynant et al. 2013). Gaudet MM et al. conducted a meta-analysis with a large sample size and analyzed three case-control studies, and concluded that cadmium and 279 lead levels in adults were not associated with an increased risk of breast 280 cancer(Gaudet et al. 2019). For 1,217 cases of kidney cancer and 1,235 normal 281 controls, experts used occupational history information to estimate occupational lead 282 exposure. Unconditional logistic regression was used to calculate the odds ratios (ORs) 283 and 95% confidence intervals (CIs) of different exposure indicators. This case-control 284 285 study found that cumulative occupational lead exposure was not associated with kidney cancer (OR=0.9,95%CI 0.7,1.3 ;Ptrend=0.80)(Callahan et al. 2019). A 286 cross-sectional study that also used the NHANES database analyzed 1,162 samples 287 and used mediation analysis to examine the mediating effect of blood lead in the 288 occurrence of cardiovascular diseases (CVD), respiratory diseases, and cancer. The 289 study results did not find a statistically significant mediating effect(Yan et al. 2024). 290

In summary, whether lead causes cancer is still controversial, and there is very 291 limited research on blood lead and bladder cancer, only one experimental study 292 revealed a relationship between lead exposure and the initiation and development of 293 294 bladder cancer. This study investigated the lead concentration levels in the blood and 295 bladder cancer tissues of 36 bladder cancer patients, and compared them with 15 normal control groups. Atomic absorption spectroscopy was used to determine the 296 lead concentration levels in each tissue sample. The results suggested that both the 297 lead concentration levels in the cancer tissues and blood of bladder cancer patients 298 were higher than those in the control group, while there was no relationship between 299 the lead concentration levels in the bladder cancer tissues and the corresponding blood 300 lead concentration(Golabek et al. 2009). Obviously, the sample size of this article is 301 too small to be persuasive. Our paper fills the gap in the research field of lead and 302

bladder cancer, and at the same time, the large sample size makes up for the 303 shortcomings of previous studies, revealing higher blood lead level was associated 304 with bladder cancer in people with  $BMI < 28 kg/m^2$ . 305

It is unclear what biologic effects might underlie a causal association between 306 lead exposure and bladder cancer, should one exist, here are the possible mechanisms. 307 308 By replacing other ions such as Ca<sup>2+</sup>, Mg<sup>2+</sup>, Fe<sup>2+</sup> and Na<sup>+</sup>, lead interferes with cellular metabolism(Flora et al. 2008), which indirectly leads to an imbalance in antioxidant 309 responses(Kasperczyk et al. 2012) that affects key enzymes and hormones(Dhir et al. 310 2011). In addition to direct damage, lead increases the levels of reactive oxygen 311 species and calcium ions in cells, reduces mitochondrial potential and reduces 312 apoptosis through the release of cytochrome(Moreira et al. 2001). Continuous lead 313 314 exposure may also affect immune function, which can induce cancer(Metryka et al. 315 2018). In addition, there are three more carcinogenic mechanisms: one is the activation of REDOX sensitive transcription factors, another involves their role as a 316 mitotic signal, and the last one is lead interferes with the process of DNA 317 repair(Genestra 2007; Silbergeld 2003). 318

Our study found that blood lead concentration was associated with bladder 319 320 cancer in the general population, but the association became insignificant after accounting for covariates. Interestingly, blood lead was still found to be associated 321 322 with bladder cancer in people with a BMI<28kg/m<sup>2</sup>, possibly because obesity represents a complex interaction of genetics, diet, metabolism, and physical activity 323 levels, obese people have more risk factors than non-obese ones, the impact of lead on 324 bladder cancer might be compensated by other confounding factors. In addition, a 325 cross-sectional study(Park and Lee 2013) using the Korean National Health and 326 Nutrition Examination Survey (KNHANES) database performed a multivariate linear 327 regression analysis on 4,522 participants. The authors found a negative correlation 328 between blood lead levels and body fat percentage and fat intake(Park and Lee 2012), 329 suggesting that body fat percentage can be used as a predictor of blood lead, which 330 partly explains our results. This interesting finding may suggest that lead may 331 accumulate more in adipose tissue while the blood level is lower, resulting in 332 underestimation of the systemic accumulation of lead. It is also possible that fat can 333 improve the body's tolerance to lead and may be a potential protective factor for lead 334 carcinogenesis. Moreover, it can be seen from Table 2 that blood lead is negatively 335 correlated with BMI, which further verifies our hypothesis. The specific reasons 336 require further research and analysis. 337

Our research has the following advantages. Firstly, our study's reliability and 338 representativeness were enhanced for the data in this study were obtained from 339 NHANES with a large sample size and covariates were considered to reduce 340 confounding factors. Furthermore, our findings were validated by Weighted 341 multivariate logistic regression and subgroup analysis to illustrate the risk of higher 342 BLL on bladder cancer formation. 343

However, this investigation also has limitations. This was a cross-sectional study 344 and the data came from an observational survey. It cannot prove causation, only 345 association. Although we have tried to minimize confounding factors, there are still 346

some limitations such as the use of single blood lead measurements, which may not accurately reflect cumulative lead exposure. In addition, the exact mechanisms behind this positive relationship are not well elucidated, because the causes of bladder cancer are extremely complex and are influenced by many genetic and environmental factors and there were still some unobserved confounding factors or information was not collected in the survey, more prospective studies should be done in the future.

### Conclusion

In conclusion, we discovered suggestive evidence of a relationship between increased BLLs and bladder cancer. Although the significant difference in general population disappeared after being adjusted for confounding factors, our findings demonstrated that bladder cancer risk increases with increased blood lead levels in people with  $BMI < 28 kg/m^2$ . Because the findings were insufficient to show a causal association, more comprehensive prospective investigations are required.

### Data availability statement

Publicly available datasets were analyzed in this study. This data can be found here: https://www.cdc.gov/nchs/NHANES/index.htm.

### **Ethics statement**

The studies involving human participants were reviewed and approved by NCHS Research Ethics Review Board (ERB). Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

## Author contributions

Hongxiao Li conducted statistical analyses and Mei Huang wrote the manuscript. All the author worked together on the design of the study, supervised the project, conducted some statistical analyses, and critically reviewed the manuscript.

## Acknowledgments

The authors would like to express my sincere gratitude to the staff and participants of the NHANES study. Without their dedication and contribution, this research would not have been possible.

## **Funding**

Guangzhou Science and Technology Plan Project (Project No. 202201010834);
Natural Science Foundation of Guangdong Province (Project No. 2021A1515010065);
Guangzhou Health Science and Technology Project (Project No. 20211A011103);
The Ministry of Education's Industry-University Cooperative Education Project in
2022 (220904082210823);

388 Guangzhou Medical University Student Innovation Ability Improvement Plan in 2022
(106);

390Doctoral Program of Guangdong Nature Foundation (2017A030310148)

391

#### References 392

- 393 [Anonymous]. 2006. Inorganic and organic lead compounds. IARC monographs on the evaluation of 394 carcinogenic risks to humans 87:1-471.
- 395 Ahn J, Park MY, Kang MY, Shin IS, An S, Kim HR. 2020. Occupational lead exposure and brain tumors:
- 396 Systematic review and meta-analysis. International journal of environmental research and public 397 health 17.
- 398 Amaral AF, Porta M, Silverman DT, Milne RL, Kogevinas M, Rothman N, et al. 2012. Pancreatic cancer 399 risk and levels of trace elements. Gut 61:1583-1588.
- 400 Basu S, Singh MK, Singh TB, Bhartiya SK, Singh SP, Shukla VK. 2013. Heavy and trace metals in
- 401 carcinoma of the gallbladder. World journal of surgery 37:2641-2646.
- 402 Callahan CL, Friesen MC, Locke SJ, Dopart PJ, Stewart PA, Schwartz K, et al. 2019. Case-control
- 403 investigation of occupational lead exposure and kidney cancer. Occupational and environmental 404 medicine 76:433-440.
- 405 Compérat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, et al. 2022. Current best
- 406 practice for bladder cancer: A narrative review of diagnostics and treatments. Lancet (London, 407 England) 400:1712-1721.
- 408 Dhir B, Sharmila P, Pardha Saradhi P, Sharma S, Kumar R, Mehta D. 2011. Heavy metal induced
- 409 physiological alterations in salvinia natans. Ecotoxicology and environmental safety 74:1678-1684.
- 410 Ebrahimi M, Khalili N, Razi S, Keshavarz-Fathi M, Khalili N, Rezaei N. 2020. Effects of lead and cadmium
- 411 on the immune system and cancer progression. Journal of environmental health science &
- 412 engineering 18:335-343.
- 413 Flora SJ, Mittal M, Mehta A. 2008. Heavy metal induced oxidative stress & its possible reversal by
- 414 chelation therapy. The Indian journal of medical research 128:501-523.
- 415 Fu Z, Xi S. 2020. The effects of heavy metals on human metabolism. Toxicology mechanisms and 416 methods 30:167-176.
- 417 Furtak G, Kozłowski M, Kwiatkowski S, Cymbaluk-Płoska A. 2022. The role of lead and cadmium in
- 418 gynecological malignancies. Antioxidants (Basel, Switzerland) 11.
- 419 Gaudet MM, Deubler EL, Kelly RS, Ryan Diver W, Teras LR, Hodge JM, et al. 2019. Blood levels of
- 420 cadmium and lead in relation to breast cancer risk in three prospective cohorts. International journal
- 421 of cancer 144:1010-1016.
- 422 Genestra M. 2007. Oxyl radicals, redox-sensitive signalling cascades and antioxidants. Cellular 423 signalling 19:1807-1819.
- 424 Golabek T, Darewicz B, Borawska M, Markiewicz R, Socha K, Kudelski J. 2009. Lead concentration in
- 425 the bladder tissue and blood of patients with bladder cancer. Scandinavian journal of urology and 426 nephrology 43:467-470.
- 427 Huang Z. 2022. Association between blood lead level with high blood pressure in us (nhanes
- 428 1999-2018). Frontiers in public health 10:836357.
- 429 Kasperczyk A, Machnik G, Dobrakowski M, Sypniewski D, Birkner E, Kasperczyk S. 2012. Gene
- 430 expression and activity of antioxidant enzymes in the blood cells of workers who were occupationally
- 431 exposed to lead. Toxicology 301:79-84.
- 432 Metryka E, Chibowska K, Gutowska I, Falkowska A, Kupnicka P, Barczak K, et al. 2018. Lead (pb)
- 433 exposure enhances expression of factors associated with inflammation. International journal of
- 434 molecular sciences 19.

- 435 Mitra P, Sharma S, Purohit P, Sharma P. 2017. Clinical and molecular aspects of lead toxicity: An update.
- 436 Critical reviews in clinical laboratory sciences 54:506-528.
- 437 Moreira EG, Vassilieff I, Vassilieff VS. 2001. Developmental lead exposure: Behavioral alterations in the
- 438 short and long term. Neurotoxicology and teratology 23:489-495.
- 439 Ni J, Li Z, Lu Y, Zhang H, Wang G, Xie J, et al. 2022. Relationship between exposure to cadmium, lead,
- 440 and mercury and the occurrence of urinary incontinence in women. Environmental science and
- 441 pollution research international 29:68410-68421.
- 442 Obeng-Gyasi E. 2019. Sources of lead exposure in various countries. Reviews on environmental health 443 34:25-34.
- 444 Park S, Lee BK. 2012. Inverse relationship between fat intake and blood lead levels in the korean adult 445 population in the knhanes 2007-2009. The Science of the total environment 430:161-166.
- 446 Park S, Lee BK. 2013. Body fat percentage and hemoglobin levels are related to blood lead, cadmium,
- 447 and mercury concentrations in a korean adult population (knhanes 2008-2010). Biological trace
- 448 element research 151:315-323.
- 449 Qayyum MA, Shah MH. 2014a. Comparative assessment of selected metals in the scalp hair and nails
- 450 of lung cancer patients and controls. Biological trace element research 158:305-322.
- 451 Qayyum MA, Shah MH. 2014b. Comparative study of trace elements in blood, scalp hair and nails of
- 452 prostate cancer patients in relation to healthy donors. Biological trace element research 162:46-57.
- 453 Qayyum S, Ara A, Usmani JA. 2012. Effect of nickel and chromium exposure on buccal cells of
- 454 electroplaters. Toxicology and industrial health 28:74-82.
- 455 Rehman K, Fatima F, Waheed I, Akash MSH. 2018. Prevalence of exposure of heavy metals and their 456 impact on health consequences. Journal of cellular biochemistry 119:157-184.
- 457 Reja D, Makar M, Visaria A, Karanfilian B, Rustgi V. 2020. Blood lead level is associated with advanced
- 458 liver fibrosis in patients with non-alcoholic fatty liver disease: A nationwide survey (nhanes
- 459 2011-2016). Annals of hepatology 19:404-410.
- 460 Rhee J, Graubard BI, Purdue MP. 2021. Blood lead levels and lung cancer mortality: An updated
- 461 analysis of nhanes ii and iii. Cancer medicine 10:4066-4074.
- 462 Richters A, Aben KKH, Kiemeney L. 2020. The global burden of urinary bladder cancer: An update. 463 World journal of urology 38:1895-1904.
- 464 Romaniuk A, Lyndin M, Sikora V, Lyndina Y, Romaniuk S, Sikora K. 2017. Heavy metals effect on breast
- 465 cancer progression. Journal of occupational medicine and toxicology (London, England) 12:32.
- 466 Ruckart PZ, Jones RL, Courtney JG, LeBlanc TT, Jackson W, Karwowski MP, et al. 2021. Update of the
- blood lead reference value united states, 2021. MMWR Morbidity and mortality weekly report 467 468 70:1509-1512.
- 469 Rusyniak DE, Arroyo A, Acciani J, Froberg B, Kao L, Furbee B. 2010. Heavy metal poisoning:
- 470 Management of intoxication and antidotes. Exs 100:365-396.
- 471 Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. 2020. Epidemiology of bladder cancer. 472 Medical sciences (Basel, Switzerland) 8.
- 473 Silbergeld EK. 2003. Facilitative mechanisms of lead as a carcinogen. Mutation research 533:121-133.
- 474 Tang J, Zhu Q, Xu Y, Zhou Y, Zhu L, Jin L, et al. 2022. Total arsenic, dimethylarsinic acid, lead, cadmium,
- 475 total mercury, methylmercury and hypertension among asian populations in the united states: Nhanes
- 476 2011-2018. Ecotoxicology and environmental safety 241:113776.
- 477 Walter K. 2023. What is lead poisoning? Jama 329:1040.

478	Wynant W, Siemiatycki J, Parent M, Rousseau MC. 2013. Occupational exposure to lead and lung
479	cancer: Results from two case-control studies in montreal, canada. Occupational and environmental
480	medicine 70:164-170.
481	Yan W, Liu X, Zhang G. 2024. Identification of potential food sources affecting blood lead levels and
482	their health hazards (cvd, respiratory diseases, cancer). The Science of the total environment
483	906:167505.
484	Zhu K, Zhang Y, Lu Q, Geng T, Li R, Wan Z, et al. 2022. Associations of exposure to lead and cadmium
485	with risk of all-cause and cardiovascular disease mortality among patients with type 2 diabetes.
486	Environmental science and pollution research international 29:76805-76815.
487	
488	
489	
490	
491	
492	
493	
494	
495	
496	
497	
498	
499	
500	
501	
502	
503	
504	
505	
506	
507	
508	
509	
510	
511	
512	
513	
514	
515	
516	
517	
518	
519	
520	
520	
~ = 1	

522 523	$T_{11} = 1$ $T_{12} = 1$ $T_{$
523	Table 1 The limit of detection (LOD)       for lead in each NHANES cycle
524	
524	
525 526	NHANES cycle lead, ug/dL
526 527	2017-2018 0.07
527	2015-2016 0.07
528	2013-2014 0.07
529	2011-2012 0.25
530	2009-2010 0.18
531	2007-2008 0.26
532	2005-2006 0.25
533	2003-2004 0.25
534	2001-2002 0.20
535	1999-2000 0.20
536	
537	
538	
539	
540	
541	
542	
543	
544	
545	
546	
547	
548	
549	
550	
551	
552	
553	
554	
555	
556	
557	
558	
559	
560	
561	
1	
562	
562 563 564	

TABLE 2 | Weighted characteristics of the study population based on serum lead. 566

	1					1
	Mean ±SD	Q1	Q2	Q3	Q4	P value
	45.55	36.84	44.77	49.24	53.14	
Age	±	±	±	±	±	< 0.0001
	16.37	13.31	15.75	15.80	16.00	
DID	2.98 ±	2.99 ±	3.07 ±	3.05 ±	2.78 ±	-0.0001
PIR	1.58	1.57	1.58	1.58	1.56	< 0.0001
	28.71	29.69	28.98	28.32	27.64	.0.0001
BMI	$\pm 6.68$	± 7.80	± 6.74	± 6.10	± 5.45	< 0.0001
	77.10	70.78	76.05	78.47	84.62	
Creatinine level	±	±	±	±	±	< 0.0001
	31.52	18.33	21.08	26.83	51.33	
Bladder cancer						< 0.0001
No	99.87	99.98	99.89	99.91	99.65	
Yes	0.13	0.02	0.11	0.09	0.35	
Sex			-			< 0.0001
Male	48.77	31.94	46.21	54.76	65.87	
Female	51.23	68.06	53.79	45.24	34.13	
Race						< 0.0001
Mexican American	8.65	9.16	8.08	8.08	9.29	
Other Hispanic	5.93	7.24	6.11	5.17	4.97	
Non-Hispanic White	67.11	66.81	67.65	68.46	65.36	
Non-Hispanic Black	11.27	10.91	10.69	10.66	13.06	
Other Race	7.04	5.88	7.47	7.62	7.32	
Education	7.01	2.00	,,	7.02	,	< 0.0001
Less than high						010001
school	17.88	10.71	15.63	19.38	27.69	
High school	24.45	21.93	24.25	24.63	27.64	
More than high	21.13	21.95		21.05		
school	57.56	67.32	60	55.86	44.52	
Unknown	0.11	0.04	0.12	0.13	0.15	
Marital	0.11	0.01	0.12	0.12	0.12	< 0.0001
Married or living						-0.0001
with partner	62.85	60.71	63.05	65.12	62.75	
Widowed, divorced, s						
eparated, or never	35.88	38.58	36.02	33.51	35.03	
married						
Unknown	1.26	0.71	0.92	1.37	2.22	
Alcohol		.,,				< 0.0001
None	10.32	12.2	10.81	9.64	8.18	
Moderate	38.75	41.81	40.51	39.07	32.57	
mouchaic	50.75	11.01	10.51	57.07	54.51	

						1
Heavy	32.67	27.72	30.79	33.23	40.34	
Unknown	18.27	18.27	17.89	18.06	18.92	
High blood pressure						< 0.0001
Yes	28.17	20.34	28.23	30.92	34.75	
No	71.51	79.56	71.51	68.72	64.61	
Unknown	0.32	0.1	0.26	0.36	0.63	
Diabetes						< 0.0001
Yes	8.02	7.44	9.08	7.94	7.63	
No	90.27	91.18	89.05	90.23	90.58	
Unknown	1.71	1.38	1.88	1.84	1.79	
Smoke						< 0.0001
Non-smoker	54.23	69.52	58.41	48.04	37.40	
Ever-smoker	23.64	18.03	22.03	26.83	28.85	
Current smoker	22.08	12.43	19.52	25.10	33.59	
Unknown	0.06	0.01	0.03	0.03	0.16	

Mean +/- SD for: Age, PIR, BMI, Creatinine level. P value was calculated by weighted linear regression model. 

% for: Bladder cancer, Sex, Race, Education, Marital, Alcohol, High blood pressure, Diabetes, Smoke.

P value was calculated by weighted chi-square test.

TABLE 5 Association between blood lead levels (µg/uf) and bladder earler.					
	Model 1	Model 2	Model 3		
	OR(95% CI) P	OR(95% CI) P	OR(95% CI) P		
	value	value	value		
Serum Lead(umol/L)	6.350 (4.048,9.961)<0.001	3.316 (1.161,9.473) 0.027	2.280 (0.575,9.038)0.243		
Serum Lead categories					
Q1 (0.000-0.039 umol/L)	Reference	Reference	Reference		
Q2 (0.040-0.062 umol/L)	4.959 (1.072,22.943) 0.042	1.821 (0.376,8.833) 0.458	1.861 (0.392,8.841) 0.436		
Q3 (0.063-0.100 umol/L)	4.076 (0.936,17.737) 0.063	0.912 (0.205,4.059) 0.904	0.767 (0.171,3.438) 0.729		
Q4 (0.101-2.960 umol/L)	16.387 (3.681,72.957)< 0.001	2.260 (0.460,11.095) 0.317	1.730 (0.367,8.146) 0.490		
P for trend	< 0.001	0.234	0.379		

#### TABLE 3 | Association between blood lead levels (µg/dl) and bladder cancer.

Model 1: No covariates were adjusted. 

Model 2: Age, Sex, Race, Education, Marital, PIR

Model 3:Age, Sex, Race, Education, Marital, PIR, BMI, Alcohol, High blood pressure, 

Diabetes, Creatinine level, Smoke. 

### 

TABLE 4 | Association between blood lead levels (µg/dl) and bladder cancer in participants with BMI < 28kg/m<sup>2</sup>.

	- 0		
	Model 1	Model 2	Model 3
	OP(050/CI) Durature	OR(95% CI) P	OR(95% CI) P
	OR(95% CI) P value	value	value
Comun	7.379	2 640 (1 280 0 640)	2.946
Serum		3.649 (1.380,9.649)	(1.025,8.465)
Lead(umol/L)	(3.959,13.751)<0.001	0.010	0.047
Serum Lead			
categories			
Q1 (0.000-0.041	Reference	Reference	Reference
umol/L)	Kelelelice	Kelelelice	Kelelence
Q2 (0.042-0.067	2.729 (0.404,18.410)	1.033(0.152,6.997)	0.914(0.133,6.265)
umol/L)	0.304	0.974	0.927
0.2 (0.069 0.100)	2 401 (0 227 19 407)	0 407(0 070 2 520)	0.349
Q3 (0.068-0.109	2.491 (0.337,18.407)	0.497(0.070,3.529)	(0.049,2.487)
umol/L)	0.373	0.486	0.295
Q4 (0.110-2.608	15.673	1.982(0.323,12.144)	1.354(0.225,8.147)
umol/L)	(2.566,95.717) 0.003	0.461	0.741
P for trend	< 0.001	0.059	0.261

Model 1: No covariates were adjusted. 

Model 2: Age, Sex, Race, Education, Marital, PIR

Model 3:Age, Sex, Race, Education, Marital, PIR, Alcohol, High blood pressure, Diabetes, Creatinine level, Smoke. 

643	TABLE 5   Association between blood lead levels ( $\mu$ g/dl) and bladder cancer in
644	participants with BMI $\ge$ 28kg/m <sup>2</sup> .

101 > 20 Kg/III		
Model 1	Model 2	Model 3
OR(95% CI) P	OR(95% CI) P	OR(95% CI) P
value	value	value
4 000	1.026	0.303
	(0.023,45.896)	(0.003,33.968)
(2.077,9.330)<0.001	0.990	0.621
Defenence	Deference	Reference
Kelerence	Kelerence	Kelerence
5.771(0.511,65.194)	2.578(0.189,35.186)	2.350(0.189,29.188)
0.159	0.479	0.507
12.195	2 106(0 269 21 551)	2.679
(1.473,100.942)		(0.297,24.202)
0.022	0.282	0.382
21.785	2 044(0 278 41 170)	2 577(0 204 22 562)
(2.655,178.747)		2.577(0.294,22.563)
0.005	0.234	0.394
< 0.001	0.3126	0.3102
	Model 1 OR(95% CI) P value 4.999 (2.677,9.336)<0.001 Reference 5.771(0.511,65.194) 0.159 12.195 (1.473,100.942) 0.022 21.785 (2.655,178.747) 0.005	Model 1Model 2OR(95% CI) POR(95% CI) Pvaluevalue4.999 $1.026$ $(2.677, 9.336) < 0.001$ $(0.023, 45.896)$ $(2.677, 9.336) < 0.001$ $0.990$ ReferenceReference5.771(0.511, 65.194) $2.578(0.189, 35.186)$ $0.159$ $0.479$ 12.195 $3.406(0.368, 31.551)$ $(1.473, 100.942)$ $0.282$ $0.022$ $3.944(0.378, 41.179)$ $0.005$ $0.254$

Model 1: No covariates were adjusted.

Model 2: Age, Sex, Race, Education, Marital, PIR 

Model 3:Age, Sex, Race, Education, Marital, PIR, Alcohol, High blood pressure, 

Diabetes, Creatinine level, Smoke. 

668 669

TABLE 6 | Weighted characteristics of the study population based on blood lead in participants with BMI < 28kg/m<sup>2</sup>.

participants with Divin		1.		1		
	Mean ±SD	Q1	Q2	Q3	Q4	P value
	44.09	35.14	42.73	48.56	52.54	
Age	±	±	±	±	±	< 0.0001
	16.85	13.20	16.14	16.30	16.68	
DID	3.03 ±	3.11 ±	3.16 ±	3.08 ±	2.70 ±	<0.0001
PIR	1.59	1.58	1.60	1.59	1.54	< 0.0001
	76.30	70.95	75.06	77.32	83.96	
Creatinine level	±	±	±	±	±	< 0.0001
	31.85	17.13	24.52	23.37	54.95	
Bladder cancer						< 0.0001
No	99.86	99.97	99.92	99.93	99.56	
Yes	0.14	0.03	0.08	0.07	0.44	
Sex						< 0.0001
Male	48.31	31.97	44.89	54.81	67.02	
Female	51.69	68.03	55.11	45.19	32.98	
Race						< 0.0001
Mexican American	7.54	7.57	6.88	7.05	8.94	
Other Hispanic	5.72	7.06	5.60	4.97	4.97	
Non-Hispanic White	68.72	69.28	70.75	69.68	64.16	
Non-Hispanic Black	9.13	8.68	7.74	8.36	12.49	
Other Race	8.88	7.40	9.02	9.94	9.43	
Education						< 0.0001
Less than high school	17.09	8.63	14.80	19.01	29.26	
High school	22.52	19.50	22.31	22.28	27.24	
More than high school	60.28	71.77	62.84	58.60	43.32	
Unknown	0.11	0.10	0.05	0.11	0.18	
Marital						< 0.0001
Married or living with partner	61.59	58.63	62.44	64.46	60.98	
Widowed,divorced,s eparated,or never	37.03	40.71	36.42	33.97	36.56	
married						
Unknown	1.39	0.67	1.14	1.57	2.46	0.000
Alcohol	10.10	11.0-	10.00			< 0.0001
None	10.10	11.95	10.89	9.04	7.89	
Moderate	41.29	45.23	42.71	41.62	33.64	
Heavy	32.15	26.35	30.03	33.14	41.61	
Unknown	16.45	16.46	16.37	16.21	16.86	

medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303198; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. If

t is made available under a	C	C-BY	-ND 4.0	International	license

High blood pressure						< 0.0001
Yes	19.05	10.56	17.93	22.67	27.66	
No	80.57	89.39	81.83	76.85	71.48	
Unknown	0.38	0.05	0.24	0.49	0.86	
Diabetes						0.0010
Yes	4.31	3.61	4.16	4.63	5.04	
No	94.70	95.70	94.78	94.28	93.74	
Unknown	0.99	0.68	1.05	1.09	1.22	
Smoke						< 0.0001
Non-smoker	53.86	71.73	57.71	45.19	35.18	
Non-smoker	21.29	15.63	20.81	25.24	24.74	
Current smoker	24.78	12.63	21.42	29.54	39.85	
Unknown	0.07	0.01	0.05	0.03	0.23	

Mean +/- SD for: Age, PIR, Creatinine level. P value was calculated by weighted linear regression model.


% for: Bladder cancer, Sex, Race, Education, Marital, Alcohol, High blood pressure, Diabetes, Smoke. P value was calculated by weighted chi-square test. 

Table 7 | Subgroup analyses of the association between blood lead and bladder cancer in participants with  $BMI \leq 28 \text{kg/m}^2$ .

eaneer in participa		<20Kg/III .			
	OR	95%CI	95%CI upp	P.value	
	UK	low	93%C1 upp	r.value	
Sex					
Male	3.64	1.32	10.06	0.01	
Female	0.00	0.00	15895.88	0.43	
Age					
<70 years	6.50	2.12	19.93	0.00	
>=70 years	3.21	0.80	12.84	0.10	
High blood					
pressure					
Yes	0.60	0.00	116.15	0.85	
No	5.71	1.62	20.12	0.01	
PIR					
<2.5	4.87	0.83	28.55	0.08	
>=2.5	1.08	0.04	27.04	0.96	

Above adjusts for Age, Sex, Race, Education, Marital, PIR, Alcohol, High blood pressure, Diabetes, Creatinine level, Smoke.

In each case, the model was not adjusted for the stratification variable itself.



medRxiv preprint doi: https://doi.org/10.1101/2024.02.22.24303198; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .





Figure 2. The association between BLL and bladder cancer, The solid red line represents the smoothcurve fit between variables. Blue bands represent the 95% confidence interval from the fit.

Adjusted variables: age, sex, race, education, marital, PIR, BMI, alcohol, high blood pressure, diabetes, creatinine level, smoke.



785

Figure 3. The association between BLL and bladder cancer stratified by BMI.

The red line represents the smoothcurve of participants with BMI < 28kg/m<sup>2</sup>. Blue
line represents the smoothcurve of participants with BMI≥28kg/m<sup>2</sup>.

Adjusted variables: Age, Sex, Race, Education, Marital, PIR, Alcohol, High blood
 pressure, Diabetes, Creatinine level, Smoke.

- 791
- 792